Bristol Myers Squibb (BMY)

[chmcnfunds]

From seeking Alpha:

Bristol-Myers Q4 top line up 22%; non-GAAP earnings up 65%; Opdivo sales up 176%; lower earnings guidance pressures shares, down 2% premarket

Jan. 26, 2017 8:42 AM ET|About: Bristol-Myers Squibb C... (BMY)|By: Douglas W. House, SA News Editor

Bristol-Myers Squibb (NYSE:BMY) Q4 results ($M): Total Revenues: 5,243 (+22.3%); Product Sales: 4,814 (+24.7%).

Net Income: 894 (+553.8%); Non-GAAP Net Income: 1,064 (+64.5%); EPS: 0.53 (+541.7%); Non-GAAP EPS: (+65.8%).

Key Product Sales: Opdivo: 1,310 (+175.8%); Eliquis: 948 (+57.5%); Orencia: 625 (+15.7%); Sprycel: 494 (+15.2%); Hep C Franchise: 226 (-50.7%); Baraclude: 296 (-4.2%); Sustiva Franchise: 246 (-21.2%); Reyataz Franchise: 206 (-24.3%).

2017 Guidance: EPS: $2.47 - 2.67 (unch); Non-GAAP EPS: $2.70 - 2.90 form $2.85 - 3.05.

Shares are down 2% premarket on robust volume.
___________________________________________________
http://seekingalpha.com/news/3237837-bristol-myers-q4-top-line-22-percent-non-gaap-earnings-65-percent-opdivo-sales-176-percent

BMY